An atypical antipsychotic
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Remoxipride (hydrochloride)

Item No. 30971

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
3-bromo-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2,6-dimethoxy-benzamide, monohydrochloride
CAS Number
73220-03-8
Molecular Formula
C16H23BrN2O3 • HCl
Formula Weight
407.7
Purity
≥98%
Formulation
A crystalline solid
Solubility(Learn about Variance in Solubility)
Water: 100 mM
SMILES
BrC1=CC=C(OC)C(C(NC[C@H]2N(CC)CCC2)=O)=C1OC.Cl
InChi Code
InChI=1S/C16H23BrN2O3.ClH/c1-4-19-9-5-6-11(19)10-18-16(20)14-13(21-2)8-7-12(17)15(14)22-3;/h7-8,11H,4-6,9-10H2,1-3H3,(H,18,20);1H/t11-;/m0./s1
InChi Key
WCPXLMIPGMFZMY-MERQFXBCSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $41

    Add

    5 mg

    $128

    Add

    10 mg

    $196

    Add
    Product Description

    Remoxipride is an atypical antipsychotic and dopamine D2 receptor antagonist (Ki = 0.2 µM).1 It is selective for the dopamine D2 receptor over a panel of 33 receptors, neurotransmitter transporters, and ion channels at 10 µM but does inhibit the sigma (σ) receptor (Ki = 0.065 µM). Remoxipride (2-20 µmol/kg, i.p.) increases striatal 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) levels in rats.2 It inhibits apomorphine-induced stereotypy and hyperactivity in rats with ED50 values of 5.6 and 0.8 µmol/kg, respectively.3 Formulations containing remoxipride have previously been used in the treatment of schizophrenia.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Leysen, J.E., Janssen, P.M.F., Schotte, A., et al. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: Role of 5HT2 receptors. Psychopharmacology (Berl) 112(1 Suppl), S40-S54 (1993).

    2. Magnusson, O., Mohringe, B., Thorell, G., et al. Effects of the dopamine D2 selective receptor antagonist remoxipride on dopamine turnover in the rat brain after acute and repeated administration. Pharmacol. Toxicol. 60(5), 368-373 (1987).

    3. Ögren, S.O., Hall, H., Kohler, C., et al. Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. Eur. J. Pharmacol. 102(3-4), 459-574 (1984).